title: Transplantation of ABO-incompatible and living unrelated donor-recipient combinations.
abstract: BACKGROUND
  According to the Japanese renal transplant registry 2005, 834 transplantations were performed using living donors. Among them 199 (23.9%) kidneys were donated from spouses (husband/wife) and 174 (20.9%) from ABO-incompatible donors. This study summarized our experience of ABO-incompatible and living unrelated, especially spousal kidney transplantation.
  
  
  METHODS
  We performed 44 cases of living donor kidney transplantation (LKT) between April 2003 and July 2007, including 14 (31.8%) from spouses (unrelated donor) who were divided into two groups: six patients (group 1; G1) from ABO-incompatible donors and eight patients (group 2; G2) from ABO-compatible donors. During the induction phase, tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone were used for immunosuppression. Basiliximab was administered on postoperative days 0 and 4. In all G1 patients plasmapheresis was performed to remove anti-AB antibodies prior to LKT, and splenectomy performed at the time of or before LKT.
  
  
  RESULTS
  Among G1, no patient died. Among G2, one patient died with a functioning graft due to a traumatic subdural hematoma. Graft survival rate was 100% in both groups. The incidence of acute rejection was 33.3% and 25.0% in G1 and G2, respectively. No patient experienced a lethal infectious complication.
  
  
  CONCLUSIONS
  Our results demonstrated that transplantation from an ABO-incompatible spousal donor was equivalent to transplantation from an ABO-compatible spousal donor. In response to the shortage of deceased donors, LKT between married couples and from ABO-incompatible donors will spread in Japan.
authors.affiliation: Division of Renal Surgery and Transplantation, Department of Urology, Jichi Medical University School of Medicine, Tochigi, Japan. nob-ishi@jichi.ac.jp
authors.forename: N
authors.initials: N
authors.lastname: Ishikawa
authors.forename: T
authors.initials: T
authors.lastname: Yagisawa
authors.forename: Y
authors.initials: Y
authors.lastname: Sakuma
authors.forename: T
authors.initials: T
authors.lastname: Fujiwara
authors.forename: A
authors.initials: A
authors.lastname: Nukui
authors.forename: M
authors.initials: M
authors.lastname: Yashi
authors.forename: N
authors.initials: N
authors.lastname: Miyamoto
mesh_terms: D000017:ABO Blood-Group System / Q000276:immunology*; D000328:Adult; D000368:Aged; D001787:Blood Group Incompatibility; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000145:classification; D012189:Retrospective Studies
chemical_list: D000017:ABO Blood-Group System; D007166:Immunosuppressive Agents